<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36111771</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6190</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Current neuropharmacology</Title><ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Potential Applications for Growth Hormone Secretagogues Treatment of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>2376</StartPage><EndPage>2394</EndPage><MedlinePgn>2376-2394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1570159X20666220915103613</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) arises from neuronal death due to complex interactions of genetic, molecular, and environmental factors. Currently, only two drugs, riluzole and edaravone, have been approved to slow the progression of this disease. However, ghrelin and other ligands of the GHS-R1a receptor have demonstrated interesting neuroprotective activities that could be exploited in this pathology. Ghrelin, a 28-amino acid hormone, primarily synthesized and secreted by oxyntic cells in the stomach wall, binds to the pituitary GHS-R1a and stimulates GH secretion; in addition, ghrelin is endowed with multiple extra endocrine bioactivities. Native ghrelin requires esterification with octanoic acid for binding to the GHS-R1a receptor; however, this esterified form is very labile and represents less than 10% of circulating ghrelin. A large number of synthetic compounds, the growth hormone secretagogues (GHS) encompassing short peptides, peptoids, and non-peptidic moieties, are capable of mimicking several biological activities of ghrelin, including stimulation of GH release, appetite, and elevation of blood IGF-I levels. GHS have demonstrated neuroprotective and anticonvulsant effects in experimental models of pathologies both <i>in vitro</i> and <i>in vivo</i>. To illustrate, some GHS, currently under evaluation by regulatory agencies for the treatment of human cachexia, have a good safety profile and are safe for human use. Collectively, evidence suggests that ghrelin and cognate GHS may constitute potential therapies for ALS.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meanti</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bresciani</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzi</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coco</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambelli</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitroulas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Surrey, Stag Hill, Guildford, GU2 7XH, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molteni</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omeljaniuk</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Biology, Lakehead University, 955 Oliver Rd, Thunder Bay, Ontario, P7B 5E1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torsello</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, Monza, 20900, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Neuropharmacol</MedlineTA><NlmUniqueID>101157239</NlmUniqueID><ISSNLinking>1570-159X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054439">Ghrelin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054440">Receptors, Ghrelin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000078604">Secretagogues</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-72-6</RegistryNumber><NameOfSubstance UI="D013006">Growth Hormone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054439" MajorTopicYN="Y">Ghrelin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054440" MajorTopicYN="N">Receptors, Ghrelin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078604" MajorTopicYN="N">Secretagogues</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013006" MajorTopicYN="N">Growth Hormone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Growth hormone secretagogues</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">ghrelin</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36111771</ArticleId><ArticleId IdType="doi">10.2174/1570159X20666220915103613</ArticleId><ArticleId IdType="pii">CN-EPUB-126330</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>